Af­ter a crush­ing PhI­II fail­ure, Cy­to­ki­net­ics says its next-gen mus­cle drug is lin­ing up well in PhII — but big chal­lenges loom

For the past 6 months, Cy­to­ki­net­ics $CYTK CEO Robert Blum has been hold­ing things to­geth­er in the wake of a dev­as­tat­ing late-stage dis­as­ter that swept away its lead mus­cle drug. He takes pride in the fact that he was able to sol­dier on with­out gut­ting the staff. And now the biotech and its part­ners at Astel­las are step­ping for­ward with their fol­low-up drug — look­ing to per­suade in­vestors that they can learn from the griev­ous set­back and make a come­back in the field of strength­en­ing pa­tients af­flict­ed by a range of ail­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER